

## The Antiglycation Ability of Typical Medicinal Plants, Natural and Synthetic Compounds: A Review

Morteza Sadeghi, Mehran Miroliaei\*

Faculty of Biological Science and Technology, Department of Cell and Molecular Biology & Microbiology, University of Isfahan, Isfahan, Iran.

### Abstract

Given the prevalence of diabetes and the increasing number of diabetics, it is essential to find medicines to decrease the chronic complications of diabetes. Several studies have demonstrated that chronic hyperglycemia and its complications are directly related to protein glycation. Thus, identifying natural inhibitors to stop glycation of proteins may play a crucial role in managing the chronic complications of diabetes. Currently, various natural and synthetic compounds with anti-glycation attributes have been reported. The use of natural compounds in herbs (medicinal and non-medicinal) may be of particular importance due to fewer side effects and a wide range of therapeutic properties. Accordingly, this mini-review provides a list of common natural medicines and synthetic compounds with anti-glycation activity. As well, it provides brief information on the formation of advanced glycosylated end products (AGEs), their side effects, and glycation prevention mechanisms.


**Keywords:** AGEs, Diabetes complication, Anti-glycation compounds

### QR Code:



**Citation:** Sadeghi M, Miroliaei M. The Antiglycation Ability of Typical Medicinal Plants, Natural and Synthetic Compounds: A Review. IJDO. 2022; 14 (1) :55-61

**URL:** <http://ijdo.ssu.ac.ir/article-1-688-en.html>

 10.18502/ijdo.v14i1.8743

### Article info:

**Received:** 08 November 2021

**Accepted:** 05 January 2022

**Published in February 2022**



This is an open access article under the (CC BY 4.0)

### Corresponding Author:

**Mehran Miroliaei**, Faculty of Biological Science and Technology, Department of Cell and Molecular Biology & Microbiology, University of Isfahan, Isfahan, Iran.

**Tel:** (98) 513 225 0049

**Email:** m.miroliaei@sci.ui.ac.ir

**Orcid ID:** 0000-0003-0916-3757

## Introduction

Almost all plasma proteins are sensitive to reactions with reducing monosaccharides, both enzymatic and non-enzymatic. The enzymatic reaction of different sugars with proteins is called glycosylation, while protein glycation is a non-enzymatic process in which 'reducing sugars' randomly interact with their free amino groups (1,2). This process was first discovered by the German scientist 'Louis Camille Maillard'. During food packaging and storage, the Maillard reaction can change the taste and color of foods. The formation of dicarbonyl compounds through the Maillard reaction is an essential step to the formation of methylglyoxal (MG), which is among the most deleterious dicarbonyl compounds playing significant role in aging and diabetes (3,4). The level of MG reaches ~0.4mM in the blood of diabetic patients, which is much higher than non-diabetics. Therefore, active dicarbonyl species such as MG cause metabolic disorders, and develop their consequences (5,6).

The glycation process does not occur under normal conditions, whilst the blood glucose levels persist chronically, glycation causes the production of advanced glycation end products (AGEs). However, extreme AGEs in the diet have been reported to induce many of diseases in humans (7,8). Accumulation of elevated level of AGEs in different tissues can play significant role in the chronic complications of diabetes. Reactive oxygen species (ROS) and reactive nitrogen species (RNS), which ultimately increases the risk of DNA mutation, cells vulnerability, activation of destructive signaling pathways, as well as inflammatory cascades, are all originate from AGE adducts. Cellular and tissue damage by AGE may result from protein modification, structure conversion, and functional degradation. Accordingly, high level of pentosidine causes wall thickness and stiffness of the heart arteries (9,10).

Accordingly, high levels of pentosidine due to the formation of AGE increase the wall

thickness and stiffness of the arteries of the heart. On the other hand, bovine serum albumin (BSA) has been shown to undergo profound structural changes due to glycation, gaining more beta plates than the native sample (6,11).

Recently, anti-glycation agents have been one of the most critical goals in slowing down the rate of aging and the spread of disease (12). *In vitro* and *in vivo* studies have established the antioxidant and anti-glycation capacity of different medicinal plants. The natural compounds of medicinal plants with high antioxidant ability, metal chelating capacity, trapping of dicarbonyl compounds, and suppression of the receptors of advanced glycation end products (RAGEs), prevent the formation or production mechanisms of AGEs (13,14). Therefore, this mini-review of medicinal herbs, natural and synthetic compounds with anti-glycation activity is introduced (Table 1), to help pharmacological researchers find the best way to treat the complications of diabetes.

### AGEs formation

There are two different pathways for the formation of AGEs that show a link between oxidation and glycation. In the first stage, oxidation of glucose in the presence of metal ions leads to the formation of ketoaldehyde radicals. After the ketoaldehyde reacts with the NH<sub>2</sub>-protein groups, ketominin is formed, leading to the production of AGEs (24). The second route involves the autoxidation of by-products, which eventually produce AGE and radical superoxide (25). Thus, free radicals damage biomolecules and alter their function. In diabetes, the production of free radicals' damage biomolecules and weakens antioxidant systems. Accordingly, antioxidants can play a key role in preventing the chronic complications of diabetes (26). Most of the plants introduced in this study have antioxidant properties.

## AGEs effects on proteins

Glycation of proteins alters the catalytic activity of enzymes, enhances the crosslinking of proteins, produces free radicals, and reduces the binding affinity of ligands and regulatory molecules (18), which are discussed below.

## Effects on protein cross-linking

Protein cross-linking occurs in the termination stage of the glycation process and leads to tissue damage. For example, protein cross-linking in the extracellular matrix hardens and reduces the flexibility of proteins, resulting in a thickened basement membrane and impaired organ function, as seen in diabetic neuropathy (27,28). *Achillea pachycephala*, *Azadirachta indica*, *Satureja hortensis*, *Thuja orientalis*, *Eucommia ulmoides* are among the medicinal herbs capable of reducing protein cross-linking (15,17).

## Enzyme Inactivation

The most likely mechanism of enzyme inactivation requires the binding of glucose to the epsilon-Lysin amine group at the active

site of the enzyme. If this epsilon-Lysin plays a major role in catalytic activity, the enzyme is inactivated (29). One of the most important examples is the glycation of the Lecithin cholesterol acyltransferase (LCAT), which leads to a loss of fat function (30).

## Production of free radicals

AGEs accumulated in the body produce active sites for the catalysis of one-electron reduction reactions that catalyze free radicals' production. These active sites, which exhibit enzyme-like properties (Nanozymes), may be produced Schiff base products that can catalyze the metal- like oxidation reactions (8,31,32).

## Effects of AGEs through binding to RAGEs

Once the AGEs connect to their receptors, RAGEs (receptors for AGEs), multiple messaging factors are activated, followed by activation of factors such as NF- $\kappa$ B, AP-1, STAT-3 NF- $\kappa$ B, AP-1 and STAT-3 are stimulated. These factors affect the expression of some genes, and can lead to a variety of

**Table 1. List of several different types of plants with antiglycation and antioxidant properties with their function**

S.NO.	Family	Herbs noun	Functional
1	Asteraceae	<i>Achyrocline satureioides</i>	Suppression the production of MG (15)
2	Lamiaceae	<i>Melissa officinalis</i>	Metal-chelating capacity, low affinity AGE to RAGE (11), and protection of hemoglobin (Hb) against fructose (16).
3	Asteraceae	<i>Achillea pachycephala</i>	MG-induced change, BSA-AGE Secondary restructuring, and Changing hydrophobic sites in the BSA-AGE (10) High levels of phenols, flavonoids, and power reducing ability (17)
4	Meliaceae	<i>Azadirachta indica</i>	Inhibit BSA-AGE, HbA1c production; reduce protein glycation and MG rate in diabetic rate.
5	Lamiaceae	<i>Satureja hortensis</i>	Prevention of $\alpha$ -helix change by hiding glycation sites and reducing solvent access (18)
6	Lamiaceae	<i>Rosmarinus officinalis</i>	Eliminate free radicals, prevent AGEs formation, and display reducing activity BSA –MG seystem (19).
7	Eucommiaceae	<i>Eucommia ulmoides</i>	Inhibition of glycation (20).
8	Fabaceae	<i>Trifolium pratense</i>	Blockage of ROS production and Hb glycation (21).
9	Cupressaceae	<i>Thuja orientalis</i>	Contains high flavonoid content that reduces the activity of the aldose rductase. Prevention the glycation by breaking the AGEs adducts (22).
10	Apiaceae	<i>Anethum graveolens</i>	Stops the schiff base level. Suppress the production of MG and $\bullet$ OH (23).
11	Lamiaceae	<i>Scutellaria baicalensis</i>	Inhibitory ability of $\alpha$ -glucosidase, $\alpha$ -amylase and AGE production
12	Solanaceae	<i>Withania somnifera</i>	Decrease of BSA-glycation.
13	Lamiaceae	<i>Salvia divinorum</i>	Antiglycative and antioxidant capacity, decrease of free radical level.
14	Ericaceae	<i>Vaccinium macrocarpon</i>	Inhibition of Hb-AGE and BSA-AGE by scavenging dicarbonyl compound.
15	Rosaceae	<i>Pyrus pyrifolia</i>	Protection of formation BSA-fructose in vitro.
16	Asteraceae	<i>Siegesbeckia orientalis</i>	Prevention the formation of amadori and carbonyl compounds.
17	Rutaceae	<i>Zanthoxylum ailanthoides</i>	Inhibition glycation and aldose reductase. Fe <sup>2+</sup> chelating, reducing power and free radical scavenging activity.
18	Scrophulariaceae	<i>Limnophila aromatica</i>	Suppression carboxymethyl lysin (CML) and decrease LDL cholestrol.

events (33). For instance, activation of NF- $\kappa$ B, regulates the immune response to infections, the process of apoptosis, and the ability of cells to survive. Accordingly, impaired NF- $\kappa$ B production leads to cancer, autoimmune diseases, inflammation, and viral infections (34-36). AP-1 is involved in cell differentiation and proliferation as well as apoptosis. Therefore, the ligand binding to RAGEs with the production of AP-1 can cause complications in these processes (37,38). STAT protein is involved in regulating many features of cell growth, viability, and differentiation. Disruption of the STAT pathway plays an essential role in tumor formation, increased angiogenesis, increased tumor viability, and inhibition of the immune system against tumors (39,40).

### The mechanisms to prevent the AGEs formation

AGEs play a key role in altering physiological processes and enhancing pathophysiological pathways. Therefore, preventing the formation of AGEs can be a promising treatment strategy to overcome the complications of diabetes and similar 'conformational diseases' such as Alzheimer's and Parkinson's diseases. Mechanisms of AGE suppression include, strengthening the cascades of the body's natural defense system, or consuming natural compounds and/or chemical inhibitors (33,34). Some of body's defense mechanisms are briefly mentioned below.

### The body's defense mechanism against the glycation

In general, our body has different mechanisms against non-enzymatic glycation of biomolecules that can be divided into five main groups consisting of, plasma amines, macrophages, glyoxalase system, relevant enzymes, and antioxidant system.

### Natural and chemical inhibitors

Due to their therapeutic properties, there is a lot of attention to AGE inhibitors. Anti-glycation agents may act by suppressing carbonyl groups, trapping MGOs, and suppressing ROS to prevent the formation of AGEs (8,41). Because natural compounds from medicinal plants have the ability to prevent the formation of AGE, they may allow the complications of diabetes to be suppressed. Table 2 shows a number of natural and synthetic compounds with anti-AGE properties as well as their performance.

### Conclusions

Identification of natural anti-glycation compounds provide useful platform for treatment of many conformational diseases. The present communication examined a list of typical plants, natural and synthetic compounds with established anti-glycation properties, which direct the pharmacological researchers to find a better way for treating the consequences of diabetes. The anti-glycation function includes suppressing the production of methylglyoxal (MG), preventing the  $\alpha$ -helix deformation, blocking the production of reactive oxygen species (ROS), and reducing

**Table 2. A number of natural and chemical antiglycation as well as their function**

Compounds	Agent type (N/C*)	Antiglycation functional	Ref.
Quercetin	N	Trapping of MGO and GO (44)	(42)
Lignan	N	Suppression of NADPH & ROS(45)	(43)
Curcumin+Chlorogenic acid	N	Neutralize the effect of AGEs aggregation	(1)
Aminocoumarins	C	Prevention of detrimental AGEs formation	(44)
Aspirin	C	acetylation of free amino groups	(45)
Resveratrol	N	Suppression of MG	(46)
Losartan	C	Decreased serum AGEs	(4)
Hesperitin+Stilben	N	Block RAGEs	(47)
Thiazolidine Derivative	C	Prevent the accumulation of AGEs in the renal glomeruli	(4)
Pyridoxamine	C	Inhibitor of the change of Amadori product to AGEs	(48)

\*:N; Natural, C; Chemical

the advanced product formation of glycation. Therefore, such studies provide useful information toward understanding the anti-glycation mechanisms and efficacy of natural compounds.

## Acknowledgments

This work was supported by Grants from Iran National Science Foundation (INSF), Grant number 99029190 and Research Council of University of Isfahan.

## Conflict of Interest

The authors declare that they have no conflict of interest.

## References

1. Rahmanifar E, Miroliaei M. Differential effect of biophenols on attenuation of AGE-induced hemoglobin aggregation. *International Journal of Biological Macromolecules*. 2020;151:797-805.
2. Dil FA, Ranjkesh Z, Goodarzi MT. A systematic review of antiglycation medicinal plants. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews*. 2019;13(2):1225-9.
3. Nagaraj RH, Sarkar P, Mally A, Biemel KM, Lederer MO, Padayatti PS. Effect of pyridoxamine on chemical modification of proteins by carbonyls in diabetic rats: characterization of a major product from the reaction of pyridoxamine and methylglyoxal. *Archives of biochemistry and biophysics*. 2002;402(1):110-9.
4. Singh RB, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. *Diabetologia*. 2001;44(2):129-46.
5. Lapolla A, Flamini R, Dalla Vedova A, Senesi A, Reitano R, Fedele D, et al. Glyoxal and methylglyoxal levels in diabetic patients: quantitative determination by a new GC/MS method. *Clinical Chemistry and Laboratory Medicine (CCLM)*. 2003;41(9):1166-73.
6. Sadeghi M, Miroliaei M, Shorakai Z. In Silico Investigation of Flavanone Compounds' Inhibitory Effects on Alpha-Amylase Enzyme and Predicting their Inhibitory Role in Diabetes Progression. *Journal of Fasa University of Medical Sciences*. 2020;10(4):2786-95.(in Persian)
7. Yeh WJ, Hsia SM, Lee WH, Wu CH. Polyphenols with antiglycation activity and mechanisms of action: A review of recent findings. *Journal of food and drug analysis*. 2017;25(1):84-92.
8. Ahmed N. Advanced glycation endproducts—role in pathology of diabetic complications. *Diabetes research and clinical practice*. 2005;67(1):3-21.
9. Lapolla A, Piarulli F, Sartore G, Ceriello A, Ragazzi E, Reitano R, et al. Advanced glycation end products and antioxidant status in type 2 diabetic patients with and without peripheral artery disease. *Diabetes care*. 2007;30(3):670-6.
10. Afshari M, Rahimmalek M, Miroliaei M. Variation in polyphenolic profiles, antioxidant and antimicrobial activity of different *Achillea* species as natural sources of antiglycative compounds. *Chemistry & biodiversity*. 2018;15(8):e1800075.
11. Miroliaei M, Khazaei S, Moshkelgosha S, Shirvani M. Inhibitory effects of Lemon balm (*Melissa officinalis*, L.) extract on the formation of advanced glycation end products. *Food chemistry*. 2011;129(2):267-71.
12. Yeh WJ, Yang HY, Pai MH, Wu CH, Chen JR. Long-term administration of advanced glycation end-product stimulates the activation of NLRP3 inflammasome and sparking the development of renal injury. *The Journal of nutritional biochemistry*. 2017;39:68-76.
13. Tan D, Wang Y, Lo CY, Sang S, Ho CT. Methylglyoxal: its presence in beverages and potential scavengers. *Annals of the New York academy of sciences*. 2008;1126(1):72-5.
14. Chen H, Virk MS, Chen F. Phenolic acids inhibit the formation of advanced glycation end products in food simulation systems depending on their reducing powers and structures. *International Journal of Food Sciences and Nutrition*. 2016;67(4):400-11.
15. Gugliucci A, Menini T. The botanical extracts of *Achyrocline satureoides* and *Ilex paraguariensis* prevent methylglyoxal-induced inhibition of plasminogen and antithrombin III. *Life Sciences*. 2002;72(3):279-92.
16. Miroliaei M, Shafaei P, Aminjafari A, Barati D, Meekins R. Protection against Advanced Glycation End Products and the Mode of Action of Lemon Balm on Hemoglobin Fructose-Mediated Glycation. *Medical Chemistry*. 2017;7:314-20.
17. Ribeiro MA, Bernardo-Gil MG, Esquivel MM. *Melissa officinalis*, L.: study of antioxidant activity in supercritical residues. *The Journal of Supercritical Fluids*. 2001;21(1):51-60.
18. Rahimmalek M, Afshari M, Sarfaraz D, Miroliaei M. Using HPLC and multivariate analyses to investigate variations in the polyphenolic



- compounds as well as antioxidant and antiglycative activities of some Lamiaceae species native to Iran. *Industrial Crops and Products*. 2020;154:112640.
19. Franco RR, da Silva Carvalho D, de Moura FB, Justino AB, Silva HC, Peixoto LG, et al. Antioxidant and anti-glycation capacities of some medicinal plants and their potential inhibitory against digestive enzymes related to type 2 diabetes mellitus. *Journal of ethnopharmacology*. 2018;215:140-6.
  20. Kim HY, Moon BH, Lee HJ, Choi DH. Flavonol glycosides from the leaves of *Eucommia ulmoides* O. with glycation inhibitory activity. *Journal of Ethnopharmacology*. 2004;93(2-3):227-30.
  21. Hosseini M, Asgary S, Najafi S. Inhibitory potential of pure isoflavonoids, red clover, and alfalfa extracts on hemoglobin glycosylation. *ARYA atherosclerosis*. 2015;11(2):133.
  22. Lee EH, Song DG, Lee JY, Pan CH, Um BH, Jung SH. Flavonoids from the leaves of *Thuja orientalis* inhibit the aldose reductase and the formation of advanced glycation endproducts. *Journal of the Korean Society for Applied Biological Chemistry*. 2009;52(5):448-55.
  23. Safari MR, Azizi O, Heidary SS, Kheiripour N, Ravan AP. Antiglycation and antioxidant activity of four Iranian medical plant extracts. *Journal of pharmacopuncture*. 2018;21(2):82.
  24. Chetyrkin S, Mathis M, Pedchenko V, Sanchez OA, McDonald WH, Hachey DL, Madu H, Stec D, Hudson B, Voziyan P. Glucose autoxidation induces functional damage to proteins via modification of critical arginine residues. *Biochemistry*. 2011 ;50(27):6102-12.
  25. Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. *The international journal of biochemistry & cell biology*. 2007 ;39(1):44-84.
  26. Goodarzi MT, Safari MR, Zal F. Cytotoxic effect of " glycated albumin-transition metal ion" on rat hepatocyte suspension. *Iranian Biomedical Journal*. 2006;10(3):139-43.
  27. Yamagishi SI, Maeda S, Matsui T, Ueda S, Fukami K, Okuda S. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes. *Biochimica et Biophysica Acta (BBA)-General Subjects*. 2012 ;1820(5):663-71.
  28. Vlassara H, Palace MR. Diabetes and advanced glycation endproducts. *Journal of internal medicine*. 2002;251(2):87-101.
  29. Ott C, Jacobs K, Haucke E, Santos AN, Grune T, Simm A. Role of advanced glycation end products in cellular signaling. *Redox biology*. 2014;2:411-29.
  30. Goh SY, Cooper ME. The role of advanced glycation end products in progression and complications of diabetes. *The Journal of Clinical Endocrinology & Metabolism*. 2008;93(4):1143-52.
  31. Goldin A, Beckman JA, Schmidt AM, Creager MA. Advanced glycation end products: sparking the development of diabetic vascular injury. *Circulation*. 2006 ;114(6):597-605.
  32. Verzijl N, DeGroot J, Thorpe SR, Bank RA, Shaw JN, Lyons TJ, et al. Effect of collagen turnover on the accumulation of advanced glycation end products. *Journal of Biological Chemistry*. 2000 ;275(50):39027-31.
  33. Reddy VP, Beyaz A. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. *Drug discovery today*. 2006;11(13-14):646-54.
  34. Marchetti P. Advanced glycation end products (AGEs) and their receptors (RAGEs) in diabetic vascular disease. *Medicographia*. 2009;31(3):257-65.
  35. Shi Y, Qian J, Zhang Q, Hu Y, Sun D, Jiang L. Advanced glycation end products increased placental vascular permeability of human BeWo cells via RAGE/NF- $\kappa$ B signaling pathway. *European Journal of Obstetrics & Gynecology and Reproductive Biology*. 2020;250:93-100.
  36. Yano T, Hagiwara Y, Ando A, Kanazawa K, Koide M, Sekiguchi T, et al. RAGE-dependent NF- $\kappa$ B inflammation processes in the capsule of frozen shoulders. *Journal of Shoulder and Elbow Surgery*. 2020;29(9):1884-91.
  37. Adamopoulos C, Piperi C, Gargalionis AN, Dalagiorgou G, Spilioti E, Korkolopoulou P, et al. Advanced glycation end products upregulate lysyl oxidase and endothelin-1 in human aortic endothelial cells via parallel activation of ERK1/2–NF- $\kappa$ B and JNK–AP-1 signaling pathways. *Cellular and Molecular Life Sciences*. 2016 ;73(8):1685-98.
  38. Dacks JB, Robinson MS. Outerwear through the ages: evolutionary cell biology of vesicle coats. *Current opinion in cell biology*. 2017;47:108-16.
  39. Sun M, Li Y, Bu W, Zhao J, Zhu J, Gu L, et al. DJC suppresses advanced glycation end products-induced JAK-STAT signaling and ROS in mesangial cells. *Evidence-Based Complementary and Alternative Medicine*. 2017;2017.
  40. Oh H, Park SH, Kang MK, Kim YH, Lee EJ, Kim DY, et al. Asaronic acid attenuates macrophage activation toward M1 phenotype through inhibition of NF- $\kappa$ B pathway and JAK-STAT signaling in glucose-loaded murine macrophages. *Journal of agricultural and food chemistry*. 2019;67(36):10069-78.
  41. Boussahel S, Cacciola F, Dahamna S, Mondello L, Saija A, Cimino F, et al. Flavonoid profile, antioxidant and antiglycation properties of *Retama sphaerocarpa* fruits extracts. *Natural product research*. 2018;32(16):1911-9.

42. Li X, Zheng T, Sang S, Lv L. Quercetin inhibits advanced glycation end product formation by trapping methylglyoxal and glyoxal. *Journal of Agricultural and Food Chemistry*. 2014;62(50):12152-8.
43. Kong X, Wang GD, Ma MZ, Deng RY, Guo LQ, Zhang JX, et al. Sesamin ameliorates advanced glycation end products-induced pancreatic  $\beta$ -cell dysfunction and apoptosis. *Nutrients*. 2015;7(6):4689-704.
44. Aminjafari A, Miroliaei M, Angelova VT, Emamzadeh R, Djukic MM, Djuric A, Saso L. Antioxidant activity and protective role on protein glycation of synthetic aminocoumarins. *Electronic Journal of Biotechnology*. 2016;19(6):43-8.
45. AAhmad MS, Ahmed N. Antiglycation properties of aged garlic extract: possible role in prevention of diabetic complications. *The Journal of nutrition*. 2006 ;136(3):796S-9S.
46. Ciddi V, Dodda D. Therapeutic potential of resveratrol in diabetic complications: in vitro and in vivo studies. *Pharmacological Reports*. 2014;66(5):799-803.
47. Li D, Mitsuhashi S, Ubukata M. Protective effects of hesperidin derivatives and their stereoisomers against advanced glycation end-products formation. *Pharmaceutical biology*. 2012;50(12):1531-5.
48. Adrover M, Vilanova B, Frau J, Muñoz F, Donoso J. The pyridoxamine action on Amadori compounds: A reexamination of its scavenging capacity and chelating effect. *Bioorganic & medicinal chemistry*. 2008;16(10):5557-69.